Anti-platelet antibodies in a natural animal model of sulphonamide- associated thrombocytopaenia

Platelets

Volumn 18, Issue 8, 2007, Pages 595-604

  Lavergne, Sidonie N ^a   Trepanier, Lauren A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Dog; Drug hypersensitivity; Sulphadiazine; Sulphamethoxazole

Indexed keywords

COTRIMAZINE; COTRIMOXAZOLE; FIBRINOGEN; FIBRINOGEN RECEPTOR; ORMETOPRIM; ROFENAID; SULFADIMETHOXINE; SULFONAMIDE; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOG; DRUG TOLERABILITY; FLOW CYTOMETRY; FLUORESCENCE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANIMALS; AUTOANTIBODIES; BLOOD PLATELETS; DOGS; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; MODELS, ANIMAL; SULFONAMIDES; THROMBOCYTOPENIA;

ANIMALIA; CANIS FAMILIARIS;

EID: 36549043931     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100701392913     Document Type: Article

References (45)

1. Bottiger LE, Westerholm B, Thrombocytopenia. I. Incidence and aetiology. Acta Med Scand 1972;191:535-540.
2. Pedersen-Bjergaard U, Andersen M, Hansen PB. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996;239:509-515.
3. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998;54:701-706.
4. Aster RH. Drug-induced immune cytopenias. Toxicology 2005;209:149-153.
5. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Safety 2004;27:1243-1252.
6. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-817.
7. Tilles SA. Practical issues in the management of hypersensitivity reactions: Sulfonamides. South Med J 2001;94:817-824.
8. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004;27:1243-1252.
9. Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993;82:2714-2718.
10. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996;15:9-50.
11. Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 2004;27:129-138.
12. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11:969-988.
13. Daftarian MP, Filion LG, Cameron W, Conway B, Roy R, Tropper F, Diaz-Mitoma F. Immune response to sulfamethoxazole in patients with AIDS. Clinical and Diagnostic Laboratory Immunology 1995;2:199-204.
14. Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994;94:1017-1024.
15. Cribb AE, Pohl LR, Spielberg SP, Leeder JS. Patients with delayed-onset sulfonamide hypersensitivity reactions have antibodies recognizing endoplasmic reticulum proteins. J Pharmacol and Experi Therap 1997;282:1064-1072.
16. Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J 2005;7:914-921.
17. Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84:176-183.
18. Kiefel V, Santoso S, Schmidt S, Salama A, Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia. Transfusion 1987;27:262-265.
19. Trepanier LA, Danhof R, Toll J, Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 2003;17:647-652.
20. Burgess JK. Molecular mechanisms of drug-induced thrombocytopenia. Curr Opin Hematol 2001;8:294-298.
21. Savage B, Bottini E, Ruggeri ZM. Interaction of integrin alpha IIb beta 3 with multiple fibrinogen domains during platelet adhesion. J Biol Chem 1995;270:28812-28817.
22. Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990;265:12267-12271.
23. Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983;258:12582-12586.
24. Shattil SJ, Brass LF, Bennett JS, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex. Blood 1985;66:92-98.
25. Boudreaux MK, Lipscomb DL. Clinical, biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs. Vet Pathol 2001;38:249-260.
26. Choquet-Kastylevsky G, Vial T, Descotes J. Allergic adverse reactions to sulfonamides. Curr Allergy Asthma Rep 2002;2:16-25.
27. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076.
28. Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: Evidence for an immune etiology. Thromb Haemost 2002;88:892-897.
29. Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombolysis 1998;5:191-202.
30. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004;2:985-992.
31. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002;99:2054-2059.
32. Kekomaki R. Platelet function and immune response. J Pediatr Hematol Oncol 2003;25(Suppl 1):S19-23.
33. Gruchalla RS. Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol 2001;108:475-488.
34. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002;3:367-377.
35. Andersson PO, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): Molecular mechanisms and implications for therapy. Expert Rev Mol Med 2004;6:1-17.
36. Gengozian N, Rice DT. Antibody-dependent cellular cytotoxicity with platelets as the target cell: Potential application to the study of immune thrombocytopenia. Clin Exp Immunol 1982;47:431-436.
37. de Belder MA, Sutton AG. Abciximab (Reopro): A clinically effective glycoprotein IIb/IIIa receptor blocker. Expert Opin Investig Drugs 1998;7:1701-1717.
38. Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991;77:2668-2676.
39. Aster RH. Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 2000;37:229-238.
40. Lerner W, Caruso R, Faig D, Karpatkin S. Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood 1985;66:306-311.
41. Lavergne SN, Danhof RS, Volkman EM, Trepanier LA. Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: A naturally occurring model of idiosyncratic drug toxicity. Clin Exp Allergy 2006;36:907-915.
42. Kurian JR, Bajad SU, Miller JL, Chin NA, Trepanier LA. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 2004;311:1171-1178.
43. Trepanier LA, Miller JL. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica 2000;30:1111-1121.
44. Bhaiya P, Roychowdhury S, Vyas PM, Doll MA, Hein DW, Svensson CK. Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts. Toxicology and applied pharmacology 2006;215:158-167.
45. Hopkins JE, Naisbitt DJ, Humphreys N, Dearman RJ, Kimber I, Park BK. Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4+ T-cells. Toxicology 2005;206:221-231.